RecruitingPhase 1Phase 2NCT07239011

Dapagliflozin in Depression

Dapagliflozin, an SGLT2 Inhibitor, From Oral Hypoglycemic Agent to Antidepressant Drug


Sponsor

Tanta University

Enrollment

60 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a medication called dapagliflozin — normally used to treat diabetes — can also help people with depression. Researchers believe it may reduce inflammation in the body and brain, which could improve mood. **You may be eligible if...** - You are 18 years or older (any gender) - You have been depressed for at least 2 months, with a moderate-to-severe score on a depression rating scale - You have a negative pregnancy test and are using effective contraception (if applicable) **You may NOT be eligible if...** - You have bipolar disorder, a personality disorder, or an eating disorder - You have a history of substance or alcohol addiction - You have a history of seizures or have received electroconvulsive therapy (ECT) - You have an inflammatory condition - You have diabetes - You have severe kidney disease - You are pregnant or breastfeeding - You have an allergy or contraindication to the study medication Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFluoxetine

Fluoxetine is an antidepressant medication of the selective serotonin reuptake inhibitor class used for the treatment of major depressive disorder, anxiety, obsessive-compulsive disorder, panic disorder, premenstrual dysphoric disorder, and bulimia nervosa.

DRUGDapagliflozin

Dapagliflozin is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.


Locations(1)

Mostafa Bahaa

Damietta, New Damietta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07239011


Related Trials